ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Brightseed Launches BioMetaControl™, a Nature-Inspired GLP-1 Companion for Metabolic Health

Powered by Forager® AI from discovery to market, the new commercial ingredient is made with proprietary bioactives to deliver clinically proven blood glucose regulation and metabolic benefits

Brightseed, the company unlocking the power of nature’s bioactives to elevate human health, today announced the commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health. This launch marks Brightseed’s expansion beyond digestive wellness into the growing field of blood glucose management and metabolic support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918348916/en/

Brightseed, the company unlocking the power of nature’s bioactives to elevate human health, today announced the commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health that supports glucose control, sustained energy, and digestive relief.

Brightseed, the company unlocking the power of nature’s bioactives to elevate human health, today announced the commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health that supports glucose control, sustained energy, and digestive relief.

A Breakthrough in Metabolic Health: NCT and NFT

Blood glucose regulation is central to overall metabolic health. HNF4-alpha is a 'master metabolic switch' that plays a pivotal role in blood glucose regulation. Brightseed's proprietary AI platform, Forager®, successfully identified bioactives, n-trans-Caffeoyl Tyramine (NCT) and n-trans-Feruloyl Tyramine (NFT), as potent HNF4-alpha agonists. By activating HNF4α, bioactives in BioMetaControl have been shown to address three key consumer and GLP-1 user needs supported in a forthcoming peer-reviewed human clinical study:

  • Glucose Control – Support healthy all-day and post-meal blood sugar levels, reduces glucose variability, and improves fasting blood glucose.
  • Sustained Energy – Help stabilize blood sugar to minimize spikes and crashes, supporting energy throughout the day (based on study subject testimonials).
  • Digestive Relief – Bioactives NCT & NFT have been shown to reduce bloating and GI discomfort, common challenges for GLP-1 users, in a separate study*.

Bioactives NCT & NFT: Clinically Proven Benefits for Blood Glucose Control, Energy (subject testimonials), and Digestive Relief

In a recent randomized, double-blind, parallel-arm, clinical study (n=126), NCT and NFT administered as BioMetaControl demonstrated a statistically significant improvement in fasting blood glucose, fasting insulin, and post-meal glucose levels in prediabetic subjects. BioMetaControl was found to improve these parameters in just 30 days.

These improvements were not only found in outcomes that represent a snapshot in time, such as fasting blood glucose, fasting insulin levels, and post-meal blood glucose levels, but also in measures of continuous glucose monitoring over a period of 24 hours.

The study results have been submitted to a peer-reviewed journal and are expected to be published in Q4 2025. In a separate, peer-reviewed and published study*, NCT and NFT at the same dose presented with digestive relief benefits emerging in under three weeks.

At a low daily dose of 120mg, BioMetaControl offers a high-impact, sustained-release solution that is easy to formulate into capsules, tablets, soft gels, or functional beverages.

Brightseed’s Forager® AI: From Discovery to Scale

Following the recent launch of Bio Gut Core, Brightseed’s clinically proven gut health ingredient, BioMetaControl is the latest example of Brightseed’s end-to-end capabilities: discovery through Forager AI, clinical validation, and production at scale. This launch demonstrates Brightseed’s ability to deliver proprietary bioactives from nature to market-ready ingredients, setting a new standard for precision bioactives in human health.

“BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager’s discovery capabilities,” said Lee Chae, Co-Founder and CEO, Brightseed. “We are excited to provide brands with a clinically proven, nature-powered solution that supports blood glucose control and complements the use of GLP-1 therapies.”

For more information about BioMetaControl and partnership opportunities, please visit https://www.brightseedbio.com/bio-meta-control/.

*DOI: https://doi.org/10.31989/bchd.v8i6.1655

About Brightseed

Brightseed®, the bioactives leader unlocking nature with AI to elevate human health, is a World Economic Global Innovator. Brightseed’s proprietary AI, Forager®, accelerates bioactive discovery, biological validation, and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Brightseed produces clinically-proven bioactives for dietary supplements, food & beverage CPG, specialty nutrition, and medical foods to power proactive health worldwide. Learn more at brightseedbio.com.

BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager’s discovery capabilities.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.